Business
GM to record $7.1 billion in fourth-quarter charges due to EV pullback, China restructuring
GM Hummer EV production in Detroit.
Photo by Jeffrey Sauger for General Motors
DETROIT – General Motors said Thursday it will record $7.1 billion in special charges for the fourth quarter of last year related to its pullback in electric vehicles and restructuring efforts in China.
The Detroit automaker said in a public filing that the charges include roughly $6 billion related to changes to its EV plans amid weakening demand and $1.1 billion, including $500 million in cash, largely related to its previously announced overhaul of a Chinese joint venture.
The charges will impact GM’s net income but not adjusted results. The announcement was broadly anticipated after the Detroit automaker in October said it was reevaluating its EV plans and would initially take a $1.6 billion charge during the third quarter as a result.
GM’s new writedowns come after crosstown rival Ford Motor said in December it expected to record about $19.5 billion in special charges related to a restructuring of its business priorities and a pullback in all-electric vehicle investments.
“We continue to believe that there is a strong future for electric vehicles, and we’ve got a great portfolio to be competitive, but we do have some structural changes that we need to do to make sure that we lower the cost of producing those vehicles,” GM CFO Paul Jacobson told CNBC in October.
Automakers commonly exclude “special items” or one-time charges from their adjusted financial results to provide investors with a clearer picture of their core, ongoing business operations.
GM said the fourth-quarter EV impairments include non-cash charges of approximately $1.8 billion. The remaining $4.2 billion is related to supplier commercial settlements, contract cancellation fees and other charges, which will have a cash impact when paid.
Additional EV charges are expected to hit this year but at a lower amount than 2025’s impairments, GM said in the filing Thursday: “We expect to recognize additional material cash and non-cash charges in 2026 related to continued commercial negotiations with our supply base, which we believe will be significantly less than the EV-related charges incurred in 2025.”
The automaker also said it may incur additional charges related to its emissions credits due to proposed regulatory changes to the greenhouse gas emission standards by the Trump administration.
GM was among the first automakers to invest billions of dollars in an EV market that ultimately didn’t materialize. At one point, the company was planning to invest $30 billion in EVs, including dozens of new models and capacity for battery production.
The U.S. EV segment overall has experienced a sales slump after the Trump administration in September put an early end to a $7,500 federal tax credit previously available for EV buyers.
Shares of GM closed Thursday at $85.13, up almost 4% on the day. The stock had a banner year in 2025, gaining more than 50% to lead all major publicly traded automakers.
GM is set to report its fourth-quarter results on Jan. 27.
Business
Could a digital twin make you into a ‘superworker’?
Firms say digital twins make staff more productive, but are they a potential legal minefield?
Source link
Business
Netflix co-founder Reed Hastings to step down as chairman
Hastings set up the company in 1997, when it rented DVDs to customers and delivered by post.
Source link
Business
Trump nominates Erica Schwartz as CDC director amid turmoil around leadership, vaccine policy
Rear Admiral Erica G. Schwartz.
U.S. Department of Health and Human Services
President Donald Trump on Thursday nominated Erica Schwartz to serve as director of the Centers for Disease Control and Prevention, concluding a monthslong effort to choose a permanent leader of the embattled health agency.
Schwartz, who will have to be confirmed by the Senate, would take over the role as Health and Human Services Secretary Robert F. Kennedy Jr. oversees a string of controversial health policy changes at the agency, including an overhaul of childhood vaccine recommendations.
Schwartz served as deputy surgeon general during the first Trump administration, where she played a major role in the U.S. response to the Covid-19 pandemic. She spent more than 20 year in uniform, including as rear admiral and chief medical officer of the Coast Guard.
Dr. Jay Bhattacharya had been acting director of the CDC — a title that expired last month under federal law. That law, called the Vacancies Act, limits the amount of time an acting officer can serve in place of a Senate-confirmed official to 210 days.
Late last month marked 210 days since the most recent CDC director, Dr. Susan Monarez, was fired.
A sign sits outside of the Centers for Disease Control and Prevention (CDC) Roybal campus in Atlanta, Georgia, U.S. March 18, 2026.
Megan Varner | Reuters
She has so far been the only person to serve as a confirmed CDC director during Trump’s second term, holding the role for under a month last summer. In congressional testimony in September, Monarez said she was fired after refusing Kennedy’s demands to approve vaccine recommendations she believed lacked scientific support.
It is unclear how Schwartz’s views on vaccines or other key public health policies compare with Kennedy’s.
Also on Thursday, Trump said he chose Sean Slovenski as deputy CDC director and chief operating officer, and Jennifer Shuford as deputy CDC director and chief medical officer. Shuford, as head of the Texas Department of State Health Services, led the state’s response to a massive measles outbreak last year, and credited vaccination and testing in declaring it over.
Schwartz’s nomination comes after a tumultuous several months for the agency, which is reeling from the leadership upheaval, plummeting morale, significant staff turnover and controversial changes to U.S. vaccine policy. Ahead of leadership departures last year, staff members were shaken by a gunman’s attack on the CDC’s Atlanta headquarters on Aug. 8.
Last month, a judge blocked a critical vaccine panel’s efforts to overhaul U.S. immunization policy. That includes an effort to reduce the number of recommended childhood shots from 17 to 11.
Trust in federal health agencies has plummeted during Kennedy’s tenure as Health and Human Services secretary, according to a February poll from health policy research group KFF, with declines across the political spectrum.
-
Entertainment1 week agoQueen Elizabeth II emotional message for Archie, Lilibet sparks speculation
-
Tech1 week agoAzure customers up in arms over ‘full’ UK South region | Computer Weekly
-
Tech1 week agoAs the Strait of Hormuz Reopens, Global Shipping Will Take Months to Recover
-
Fashion1 week agoCII submits 20-pt agenda to Indian govt to back firms hit by Iran war
-
Tech1 week agoThis AI Button Wearable From Ex-Apple Engineers Looks Like an iPod Shuffle
-
Politics7 days agoIndian airlines hit hardest after Dubai limits foreign flights until May 31
-
Entertainment4 days agoPalace left in shock as Prince William cancels grand ceremony
-
Politics7 days agoChinese, Taiwanese will unite, Xi tells Taiwan opposition leader
